Skip to content
Opiant_logo Opiant Pharmaceuticals
Main Menu
  • Newsletter
  • Contact
  • Careers
  • Twitter
  • LinkedIn
  • About
    • Our Mission
    • Management Team
    • Board of Directors
    • Medical Advisory Board
    • Media
    • Careers
  • Therapy Areas
    • Opioid Use Disorder
    • Alcohol Use Disorder
    • Acute Cannabinoid Overdose
    • Patients & Families
    • Scientific Publications
  • Products & Pipeline
    • Pipeline Chart
  • Media Resources
    • News Releases
    • Resources
    • Perspectives
    • In the news
    • Community
    • Leadership
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Financial & Filings
      • SEC Filings
      • Annual Reports & Proxy Statements
Molecular Structure image

Pipeline

IndicationProgram / Regulatory PathwayPreclinicalPhase IPhase IIPhase IIINDAFDA ApprovalPartner
Opioid OverdoseNARCAN® Nasal SprayApproved
Opioid OverdoseOPNT003 Nalmefene Nasal Spray
Preclinical
Phase I
Phase II
Phase III
NDA
FDA Approval
Alcohol Use DisorderOPNT002 Opioid Antagonist Nasal Spray
Preclinical
Phase I
Phase II
Phase III
NDA
FDA Approval
Acute Cannabinoid OverdoseOPNT004 Drinabant (CB-1 Antagonist)
Preclinical
Phase I
Phase II
Phase III
NDA
FDA Approval
Sanofi logo
  • Twitter
  • LinkedIn
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Site Map
© Opiant Pharmaceuticals, 2022. All Rights Reserved.